Drug intelligence / Profile preview

Non-Typhoidal Salmonella conjugate vaccine

Development stage
Unknown
Lead developer
Bharat Biotech
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The Non-Typhoidal Salmonella (NTS) conjugate vaccine is a bivalent vaccine candidate developed by Bharat Biotech to prevent invasive Non-Typhoidal Salmonella (iNTS) infections. The vaccine targets the two most common serovars associated with iNTS disease: *Salmonella enterica* serovar Typhimurium and *Salmonella enterica* serovar Enteritidis. It utilizes a conjugate platform where the O-polysaccharide (O-antigen) from these bacteria is chemically linked to a carrier protein, such as tetanus toxoid. This conjugation enhances the immune response by engaging T-cells, which is particularly critical for providing protection in infants and young children who do not respond well to pure polysaccharide vaccines. The vaccine is currently in Phase 3 clinical development, aiming to address a significant public health burden in sub-Saharan Africa and other endemic regions.

Other names
NTS ConjugatesNon-Typhoidal Salmonella vaccineiNTS vaccineBharat Biotech NTS vaccine
02

Targets

O9 (Salmonella Enteritidis O-antigen polysaccharide)Salmonella enterica serovar Typhimurium O:4 O-antigen polysaccharide

Beyond the preview

Go deeper on Non-Typhoidal Salmonella conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-Typhoidal Salmonella conjugate vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call